In this review article from Biomarkers in Medicine, researchers explore the current application of blood-based markers to assess amyloid-β pathology.
A simple blood test could detect the earliest changes caused by Huntington’s disease, even before scans pick up any signs in the brain.
This Editorial explores the potential use of biomarkers such as TGF-β, neurofilament light polypeptide, autotaxin, α-syn and complement for AD diagnosis.
Researchers discover that an elevated volume of subarachnoid cerebrospinal fluid could be associated with a higher risk of developing autism.
The effects of microgravity on CSF could be responsible for the visual impairment intracranial pressure often seen in long-duration astronauts.
Study suggests that white matter injury and amyloid deposition could provide an objective tool to assess individuals who are at risk of developing progressive neurodegeneration.
In celebration of Neuroscience Nurses Week, we talk to Rowena G. Ronquillo, Registered Nurse and Clinical Leader at the Neuroscience Center at Sinai Hospital in Baltimore (MD, USA).
Ask the experts: should we screen for Alzheimer’s disease? (Part 3: Current diagnostics & future biomarkers)
Part 2 of our first ‘Ask the experts’ discusses current diagnostics for Alzheimer’s disease and future opportunities in the form of biomarkers.
Amid the strong clinical need for differential diagnostic biomarkers for parkinsonian disorders, this article examines the proteolytic signatures of patients with multiple system atrophy and non-neurodegenerative controls.
This review explores the current status of diagnosis, management and treatment of CNS germ cell tumors as well future directions for therapies.